Previous 10 | Next 10 |
BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and D...
Shares of CorMedix Inc. (CRMD) are down 13% in morning trading.Shares of the infectious and inflammatory diseases focused biopharma have been on a tear, gaining 124% in the last month and 89% in the last 5 days alone.The stock's bullishness appears centered on th...
BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been...
CorMedix (CRMD) shares climbs 14% in premarket , after the company said the FDA has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January 14, 2021, to discuss the marketing application for Defencath, to be used as a catheter lock ...
PDUFA date remains February 28, 2021 Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. ...
Paul Singer's Elliott Management exits Cinemark Holdings (CNK) and AT&T (T), according to the firm's 13F filing for Q3.Takes new stake in Cubic (CUB) with 1.5M shares, Uniti Group (UNIT) with ~20.5M shares, and Noble Energy (NBL) with ~15.8M shares.Boosts stake in CorMedix (CRMD) to ~1.76...
Candidate could get approval. But IP not very strong. Not enough funds for development pipeline. For further details see: CorMedix: Patent Coverage Is A Problem
CorMedix Inc. (CRMD) Q3 2020 Earnings Conference Call November 5, 2020 16:30 ET Company Participants Dan Ferry - Investor Relations Khoso Baluch - Chief Executive Officer Phoebe Mounts - Executive Vice President and General Counsel Matt David - Executive Vice President and Chief Financial Off...
CorMedix Inc. (CRMD) Q3 2020 Earnings Conference Call October 5, 2020 4:20 PM ET Company Participants Dan Ferry – Managing Director of LifeSci Advisors Khoso Baluch – Chief Executive Officer Phoebe Mounts – Executive Vice President and General Counsel Matt David – ...
CorMedix (CRMD): Q3 GAAP EPS of -$0.22 beats by $0.04.Revenue of $0.93M (+1450.0% Y/Y) beats by $0.89M.Shares +1.5% AH.Press Release For further details see: CorMedix EPS beats by $0.04, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...